Nanog, as a key cancer stem cell marker in tumor progression.
Cancer stem cells
Nanog
Tumor Marker
Tumor progression
Journal
Gene
ISSN: 1879-0038
Titre abrégé: Gene
Pays: Netherlands
ID NLM: 7706761
Informations de publication
Date de publication:
15 Jun 2022
15 Jun 2022
Historique:
received:
06
11
2021
revised:
16
02
2022
accepted:
18
03
2022
pubmed:
27
3
2022
medline:
14
5
2022
entrez:
26
3
2022
Statut:
ppublish
Résumé
Cancer stem cells (CSCs) are a small population of malignant cells that induce tumor onset and development. CSCs share similar features with normal stem cells in the case of self-renewal and differentiation. They also contribute to chemoresistance and metastasis of cancer cells, leading to therapeutic failure. To identify CSCs, multiple cell surface markers have been characterized, including Nanog, which is found at high levels in different cancers. Recent studies have revealed that Nanog upregulation has a substantial association with the advanced stages and poor prognosis of malignancies, playing a pivotal role through tumorigenesis of multiple human cancers, including leukemia, liver, colorectal, prostate, ovarian, lung, head and neck, brain, pancreatic, gastric and breast cancers. Nanog through different signaling pathways, like JAK/STAT and Wnt/β-catenin pathways, induces stemness, self-renewal, metastasis, invasiveness, and chemoresistance of cancer cells. Some of these signaling pathways are common in various types of cancers, but some have been found in one or two cancers. Therefore, this review aimed to focus on the function of Nanog in multiple cancers based on recent studies surveying the suitable approaches to target Nanog and inhibit CSCs residing in tumors to gain favorable results from cancer treatments.
Identifiants
pubmed: 35337852
pii: S0378-1119(22)00267-0
doi: 10.1016/j.gene.2022.146448
pii:
doi:
Substances chimiques
NANOG protein, human
0
Nanog Homeobox Protein
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
146448Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.